International Clinics
Daily
FDA grants accelerated approval to neladalkib for ALK-positive lung cancer
On 17 November 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib).
On 17 November 2026 the FDA granted accelerated approval to Nelkarmi (neladalkib).
Nothing more to show